BioCentury
ARTICLE | Clinical News

hGH-CTP: Ph III started

January 5, 2017 10:00 PM UTC

Opko began an open-label, U.S. Phase III trial to evaluate once-weekly subcutaneous hGH-CTP vs. once-daily subcutaneous Genotropin somatropin in about 220 pre-pubertal children ages ≥3. Pfizer and Opk...

BCIQ Company Profiles

Opko Health Inc.

Pfizer Inc.